Patent intelligence · US
US 11077077
Therapeutic compounds, formulations, and uses thereof
Therapeutic compounds, formulations, and uses thereof
Patent details — US 11077077
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 3, 2021
- Expiration
- Jul 29, 2041
- Applicant
- Tvardi Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/18, A61K47/10, A61K47/26
Quick answer
US 11077077 (Therapeutic compounds, formulations, and uses thereof) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/18, A61K47/10, A61K47/26, A61K47/44, A61K9/0053
More from Tvardi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11077077?
US 11077077 (Therapeutic compounds, formulations, and uses thereof) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11077077?
Tvardi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11077077 expire?
Our index shows an expiration date of Jul 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.